DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
June 16, 2022

DiabetesWise Pro founder highlights the 3 most beneficial website features to help clinicians compare all the available CGMs, delivery systems, AIDs, and smart pens.

Patients with Diabetes Face Higher Risk for Left-sided Valvular Stenotic Lesions
June 14, 2022

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

Prediabetes Independently Associated with MI, PCI, CABG: A "Wake-up Call," Study Authors Say
June 13, 2022

ENDO 2022: The large US analysis found persons with prediabetes had increased odds for heart attack of 25%, for PCI of 45%, and had nearly double the risk of having CABG.

Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data
June 08, 2022

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI
June 07, 2022

ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.

Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c
June 07, 2022

ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.

Finerenone Cardiorenal Effects in T2D Consistent Across Baseline HbA1c, Disease Duration
June 07, 2022

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

Younger Age and Higher HbA1c Among Factors Linked to CGM Uptake in New Study
June 06, 2022

ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.

Patients with Diabetes Up to 4-times More Likely to Develop Long COVID-19
June 04, 2022

ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.

CGM News: FreeStyle Libre 3 Cleared by FDA for Persons Aged 4 Years and Older with Diabetes
June 02, 2022

The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.